摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-phenyl-4-(piperazin-1-yl)naphthalene-1-sulfonamide | 782445-10-7

中文名称
——
中文别名
——
英文名称
N-phenyl-4-(piperazin-1-yl)naphthalene-1-sulfonamide
英文别名
N-phenyl-4-piperazin-1-ylnaphthalene-1-sulfonamide
N-phenyl-4-(piperazin-1-yl)naphthalene-1-sulfonamide化学式
CAS
782445-10-7
化学式
C20H21N3O2S
mdl
——
分子量
367.472
InChiKey
NZXOUGBBFQFCLF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    69.8
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    4-氟萘-1-磺酰氯吡啶 作用下, 以 二氯甲烷 为溶剂, 反应 6.0h, 生成 N-phenyl-4-(piperazin-1-yl)naphthalene-1-sulfonamide
    参考文献:
    名称:
    [EN] COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
    [FR] COMPOSÉS SE LIANT À LA PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9)
    摘要:
    本公开涉及与PCSK9结合的新化合物、方法和组合物,从而调节PCSK9前蛋白酶酶活性。本公开的化合物包括化合物式(I)。
    公开号:
    WO2017147328A1
点击查看最新优质反应信息

文献信息

  • New compounds
    申请人:——
    公开号:US20030158202A1
    公开(公告)日:2003-08-21
    The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system. 1
    本发明涉及一般式(I)的取代磺胺基化合物,其中P是磺胺基或酰胺基取代的磺酸,这些化合物可能有助于预防和治疗与肥胖、2型糖尿病和/或中枢神经系统紊乱有关的医疗状况。
  • Compounds
    申请人:Johansson Gary
    公开号:US20070066598A1
    公开(公告)日:2007-03-22
    The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.
    本发明涉及一般式(I)的取代磺酰胺化合物,其中P是磺酰胺或酰胺取代的磺酸,这些化合物可能有用于预防和治疗与肥胖症、2型糖尿病和/或中枢神经系统紊乱有关的医疗条件。
  • New Compounds
    申请人:Caldirola Patrizia
    公开号:US20100222330A1
    公开(公告)日:2010-09-02
    The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.
    本发明涉及一般式(I)的取代磺酰胺化合物,其中P是磺酰胺或酰胺取代的磺酸,这些化合物可能用于预防和治疗与肥胖症、2型糖尿病和/或中枢神经系统紊乱有关的医疗状况。
  • COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
    申请人:Portola Pharmaceuticals, Inc.
    公开号:US20190119236A1
    公开(公告)日:2019-04-25
    The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).
  • COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9
    申请人:SRX Cardio, LLC
    公开号:US20210032214A1
    公开(公告)日:2021-02-04
    The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).
查看更多